<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075569</url>
  </required_header>
  <id_info>
    <org_study_id>03-10-251</org_study_id>
    <secondary_id>AECOM-0309225</secondary_id>
    <secondary_id>NCI-5850</secondary_id>
    <nct_id>NCT00075569</nct_id>
  </id_info>
  <brief_title>SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia</brief_title>
  <official_title>SGN-00101 (HspE7) Immunotherapy Of CIN III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer or to treat early cancer. SGN-00101 may be effective in preventing the&#xD;
      development of cervical cancer in patients who have cervical intraepithelial neoplasia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well SGN-00101 immunotherapy works in preventing&#xD;
      cervical cancer in patients with grade III cervical intraepithelial neoplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the rate of regression at 4-7 months in patients with grade III cervical&#xD;
           intraepithelial neoplasia (CIN III) treated with SGN-00101 immunotherapy.&#xD;
&#xD;
        -  Compare the rate of regression at 4-7 months with expected outcome in patients immunized&#xD;
           with this vaccine.&#xD;
&#xD;
        -  Determine the toxic effects and recovery from possible toxic effects of this vaccine in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine induction of cell-mediated immune responses against human papillomavirus (HPV)&#xD;
           E7 peptides before and after treatment in patients immunized with this vaccine&#xD;
&#xD;
        -  Correlate regression of disease with enhanced immunologic responses in patients&#xD;
           immunized with this vaccine.&#xD;
&#xD;
        -  Correlate seropositivity of HPV-16 virus-like particles (VLP16) with vaccine-induced&#xD;
           regression of CIN III in patients immunized with this vaccine.&#xD;
&#xD;
        -  Determine the efficacy of this vaccine in patients whose CIN III is associated with&#xD;
           HPV-16 infection vs other HPV types.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
      All patients receive SGN-00101 subcutaneously once monthly on months 1-3 (for a total of 3&#xD;
      vaccinations) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Group 1: Four months after the first vaccination, patients undergo therapeutic and&#xD;
           diagnostic loop electrosurgical excision procedure (LEEP) or core biopsy.&#xD;
&#xD;
        -  Group 2: Six months after the first vaccination, patients undergo therapeutic and&#xD;
           diagnostic LEEP or core biopsy.&#xD;
&#xD;
      Patients in group 1 are followed at 12 months and patients in group 2 are followed at 14&#xD;
      months after the first vaccination.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 66 patients (36 for group 1 and 30 for group 2) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of regression</measure>
    <time_frame>4 months after completion of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>4 months after completion of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>1 month follow-up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 month follow-up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HspE7</intervention_name>
    <description>500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.</description>
    <arm_group_label>1 month follow-up</arm_group_label>
    <arm_group_label>2 month follow-up</arm_group_label>
    <other_name>SGN-00101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed grade III cervical intraepithelial neoplasia (CIN III) with&#xD;
             colposcopically visible cervical lesions&#xD;
&#xD;
          -  No positive endocervical curettage or inadequate colposcopy at the time of initial&#xD;
             cervical biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Lymphocyte count at least 500/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  No significant hematologic disease that is uncontrolled with standard therapy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  Liver enzymes no greater than 2.5 times normal&#xD;
&#xD;
          -  No significant hepatic disease that is uncontrolled with standard therapy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  No significant renal disease that is uncontrolled with standard therapy&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiovascular disease that is uncontrolled with standard therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No significant respiratory disease that is uncontrolled with standard therapy&#xD;
&#xD;
          -  No history of asthma&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No clinical evidence of immunosuppression&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological activity as those used in this study&#xD;
&#xD;
          -  No history of a positive purified protein derivative (PPD) or Tine test&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Good health based upon the results of a medical history, physical examination, vital&#xD;
             signs, and laboratory profile&#xD;
&#xD;
          -  No uncontrolled chronic disease&#xD;
&#xD;
               -  Chronic disease requiring medication is allowed provided the patient is not&#xD;
                  taking immunosuppressive drugs&#xD;
&#xD;
          -  No significant endocrine (e.g., thyroid or diabetes), neurologic, gastrointestinal, or&#xD;
             dermatologic disease that is uncontrolled with standard therapy&#xD;
&#xD;
          -  No other underlying or unstable disease that would be exacerbated by the study&#xD;
             treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior BCG vaccination&#xD;
&#xD;
          -  No other concurrent vaccine therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 30 days since prior oral or parenteral glucocorticoid steroid&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior participation in another investigational study&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies intended to&#xD;
             treat CIN&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn D. Runowicz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark H. Einstein, MD, MS</last_name>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, Goldberg GL, Runowicz CD. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol. 2007 Sep;106(3):453-60. Epub 2007 Jun 22.</citation>
    <PMID>17586030</PMID>
  </results_reference>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

